Glaukos Reports Strong Q3 2026 Results Driven by iDose TR and Epioxa Launches
Glaukos Corporation (GKOS) reported significant third-quarter growth, with net sales reaching $211.0 million, a 58% increase year-over-year. This performance was primarily fueled by the successful commercial launches of iDose TR and Epioxa. The company achieved profitability on a non-GAAP basis, reporting diluted EPS of $0.47 compared to a loss in the prior year period. Following the third-quarter outperformance, Glaukos raised its full-year 2026 net sales guidance to a range of $775 million to $785 million and provided preliminary 2027 revenue guidance of approximately $1 billion. While management noted some initial market enthusiasm regarding Epioxa's ramp-up pace, the company continues to expand its site-of-care network and payer access, maintaining high gross margins as it shifts toward higher-margin pharmaceutical products.
Tickers: $GKOS
Topics: corneal health earnings report glaucoma treatment guidance raise pharmaceutical sales revenue growth